Reduced expression of the WW domain-containing oxidoreductase in human hematopoietic malignancies.
The role of the WW domain-containing oxidoreductase (WWOX) gene in multiple types of solid human cancers has been documented extensively thus far. Recently, we investigated thein vitroeffects ofWWOXoverexpression and observed marked growth arrest in human leukemia cells; however, the clinical characterization ofWWOXin leukemia remains poorly investigated. The present study evaluated theWWOXexpression profiles of 182 patients with leukemia of different types and 5 leukemic cell lines, using reverse transcription-polymerase chain reaction and immunofluorescence analysis. The results found thatWWOXmRNA and WWOX protein expression was significantly reduced or absent in the leukemia cases and cell lines compared with paired controls. TheWWOX-positive rate was also lower in the leukemia cases compared with the rate of the normal controls. Notably, theWWOXlevel was reduced in newly diagnosed and relapsed cases, or in chronic myelogenous leukemia in the blastic phase, yet elevated in remission samples. Moreover,WWOX-negative cases exhibitedWWOXexpression restoration following induced remission. These findings suggest that WWOX may contribute to the occurrence and development of leukemia, and that it has potential to be a good biomarker or predictor for leukemia therapy.
Department of Clinical Laboratory, Fujian Provincial Key Laboratory of Tumor Biotherapy, Fujian Provincial Cancer Hospital, Teaching Hospital of Fujian Medical University, Fuzhou, Fujian 350014, P.R. China.
Lingqing
L
Luo
Department of Clinical Laboratory, Fujian Provincial Key Laboratory of Tumor Biotherapy, Fujian Provincial Cancer Hospital, Teaching Hospital of Fujian Medical University, Fuzhou, Fujian 350014, P.R. China.
Yan
Y
Chen
Department of Cardiovasology, Affiliated Mindong Hospital, Fujian Medical University, Fuan, Fujian 355000, P.R. China.
Xiao
X
Cheng
Department of Clinical Laboratory, Fujian Provincial Key Laboratory of Tumor Biotherapy, Fujian Provincial Cancer Hospital, Teaching Hospital of Fujian Medical University, Fuzhou, Fujian 350014, P.R. China; Department of Clinical Laboratory, School of Medical Technology and Engineering, Fujian Medical University, Fuzhou, Fujian 350004, P.R. China.
Yazhen
Y
Lin
Department of Clinical Laboratory, Fujian Provincial Key Laboratory of Tumor Biotherapy, Fujian Provincial Cancer Hospital, Teaching Hospital of Fujian Medical University, Fuzhou, Fujian 350014, P.R. China; Department of Clinical Laboratory, School of Medical Technology and Engineering, Fujian Medical University, Fuzhou, Fujian 350004, P.R. China.
Xiaodan
X
Fu
Department of Clinical Laboratory, Fujian Provincial Key Laboratory of Tumor Biotherapy, Fujian Provincial Cancer Hospital, Teaching Hospital of Fujian Medical University, Fuzhou, Fujian 350014, P.R. China.
Dan
D
Li
Department of Clinical Laboratory, Fujian Provincial Key Laboratory of Tumor Biotherapy, Fujian Provincial Cancer Hospital, Teaching Hospital of Fujian Medical University, Fuzhou, Fujian 350014, P.R. China; Department of Clinical Laboratory, School of Medical Technology and Engineering, Fujian Medical University, Fuzhou, Fujian 350004, P.R. China.
Zhaolei
Z
Cui
Department of Clinical Laboratory, School of Medical Technology and Engineering, Fujian Medical University, Fuzhou, Fujian 350004, P.R. China.
Donghong
D
Lin
WW domain-containing oxidoreductase; clinical characterization; expression; hematopoietic malignancies; leukemia